Riskpilot← Back to searchSign inGet full accessColoplast Oy
OYActiveY-tunnus 2394871-8Äyritie 12-BWholesale of pharmaceutical and medical goods · NACE 4646Est. 201131 employees
Revenue 2025
EUR 19,7M
+2% vs 2024
EBITDA margin
6.2%
-24% vs 2024
Equity ratio
25.3%
Financial strength
Net profit 2025
EUR 988K
-26% vs 2024
| Revenue | EUR 19,7M | +2% |
| EBITDA | EUR 1,2M | -24% |
| Net profit | EUR 988K | -26% |
| Total assets | EUR 9M | -98% |
| Equity | EUR 2,3M | -24% |
| Employees | 31 | — |
Legal name
Coloplast Oy
Y-tunnus number
2394871-8
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. maaliskuuta 2011
Share capital
EUR 2 500
Employees
31 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääketukkukauppa.
Address
Äyritie 12-B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 17 208 | 17 665 | 17 536 | 18 502 | 19 202 | 19 395 | 19 731 |
| Staff expenses | −2 045 | −2 201 | −2 535 | −2 829 | −2 660 | −2 700 | −2 784 |
| EBITDA | 1 059 | 1 160 | 1 252 | 1 249 | 1 398 | 1 611 | 1 219 |
| Depreciation & amort. | −2 | −2 | −26 | −35 | −34 | −34 | −35 |
| EBIT | 1 056 | 1 158 | 1 226 | 1 214 | 1 364 | 1 577 | 1 184 |
| Net financials | −7 | −10 | −15 | −6 | 5 961 | 115 | 63 |
| Profit before tax | 1 050 | 1 148 | 1 211 | 1 208 | 113 200 | 1 692 | 1 247 |
| Tax | 225 | 238 | 246 | 2 | −0 | −0 | 260 |
| Net profit | 825 | 910 | 965 | 959 | 112 905 | 1 338 | 988 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 3 563 | 4 109 | 7 674 | 7 631 | 805 005 | 561 860 | 9 020 |
| Equity | 1 396 | 1 506 | 1 571 | 2 530 | 2 765 878 | 2 997 | 2 284 |
| Long-term debt | 283 | 272 | 342 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 884 | 2 332 | 5 761 | 0 | 5 468 | 5 052 | 6 736 |
| Total debt | 2 167 | 2 604 | 6 103 | 5 101 | 546 770 | 5 052 | 6 736 |
EBITDA margin
6.2%
This company
15.8%
Market median
-61% vs market
20192025
Equity ratio
25.3%
This company
38.2%
Market median
-34% vs market
20192025
Return on equity
43.2%
This company
18.4%
Market median
+135% vs market
20192025
Net profit margin
5.0%
This company
8.1%
Market median
-38% vs market
20192025
Asset turnover
2.19×
This company
1.12×
Market median
+96% vs market
20192025
Debt / equity
2.95×
This company
0.62×
Market median
-376% vs market
20192025
- Annual report 2025Filed via PRH / YTJ · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via PRH / YTJ · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via PRH / YTJ · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via PRH / YTJ · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via PRH / YTJ · Period 2018-10-01 – 2019-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KA Audit | Audit | 2011 | — | — |
RG Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
MA Person with significant control | Person with significant control | 2024 | — | — |
MM Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2014 | — | — | |
| Chairperson | 2020 | — | — | |
| Chairperson | 2014 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Coloplast Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kari Antero Lydman | Audit | 0 companies |
| Robert Gustaf Hedberg | Chief Executive Officer | 0 companies |
| Mika Antero Lehtonen | Person with significant control | 0 companies |
| Mia Maria Karppila | Chief Executive Officer | 0 companies |
| Claus Lundbæk Ottosen | Board of Directors | 0 companies |
| Peter Volkers | Board of Directors | 0 companies |
| Henning Reichardt | Chairperson | 0 companies |
| Alain Michel Hervé Morvan | Chairperson | 0 companies |
| Henrik Deneke | Board of Directors | 0 companies |
| Hea Vinskov | Board of Directors | 0 companies |
| Anton Mailing Mikkelsen | Board of Directors | 0 companies |